Introduction {#section5-1470320318770546}
============

Chronic obstructive pulmonary disease (COPD) is characterised by persistent respiratory symptoms and airflow limitation, and it has ranked as the third killer in the world as per the latest statistics.^[@bibr1-1470320318770546],[@bibr2-1470320318770546]^ Although several modifiable risk factors such as cigarette smoking and exposure to ambient air pollution have been identified, there is substantial evidence for the contribution of a heritable component to COPD susceptibility. For instance, a twin study estimated that inherited genetic susceptibility contributed to 60% of COPD risk.^[@bibr3-1470320318770546]^ Genome-wide association studies have succeeded in showing convincingly that COPD is a multifactorial polygenic disease.^[@bibr4-1470320318770546],[@bibr5-1470320318770546]^ Despite tremendous advances gained in heritable insights, it still remains a challenge to unlock the genetic basis of COPD, because of apparent inconsistency from underpowered individual studies.

It is widely recognised that the gene encoding angiotensin-converting enzyme (*ACE*) is a COPD susceptibility candidate.^[@bibr6-1470320318770546][@bibr7-1470320318770546][@bibr8-1470320318770546]--[@bibr9-1470320318770546]^ Low ACE activity was identified to play a beneficial role in the development of COPD. The genomic sequence of the *ACE* gene is polymorphic, and thereof an insertion/deletion (I/D) polymorphism (rs4646994) in intron 16 is found to be highly associated with the circulating ACE level.^[@bibr10-1470320318770546]^ In particular, carriers of the DD genotype of this polymorphism had higher cellular and circulating levels of ACE, as well as power/sprint performance related to those with the II genotype.^[@bibr11-1470320318770546]^ It is thus reasonable to hypothesise that the *ACE* gene I/D polymorphism is a promising candidate locus in susceptibility to COPD. In fact, the association of the *ACE* gene I/D polymorphism with COPD risk has been extensively studied in the medical literature, while the findings are inconsistent and inconclusive.^[@bibr6-1470320318770546][@bibr7-1470320318770546][@bibr8-1470320318770546]--[@bibr9-1470320318770546]^ A comprehensive evaluation of this inconsistency is obviously needed for such a conclusion to be drawn more firmly. To test this hypothesis and yield more information, we conducted a systematic meta-analysis of published data on the *ACE* gene I/D polymorphism in association with COPD. In addition, we attempted to interrogate the association of this polymorphism with pulmonary function and circulating ACE changes.

Methods {#section6-1470320318770546}
=======

The conduct of this meta-analysis conformed to the guidelines of the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement.^[@bibr12-1470320318770546]^ The PRISMA checklist and flow diagram are presented in [Supplementary Table 1](http://journals.sagepub.com/doi/suppl/10.1177/1470320318770546) and [Supplementary Figure 1](http://journals.sagepub.com/doi/suppl/10.1177/1470320318770546), respectively.

Search strategy {#section7-1470320318770546}
---------------

We searched major online public databases including Medline/PubMed, EMBASE (Excerpta Medica database) and Web of Science for studies published before 25 August 2017. We used heading search strategy with the terms: ('ACE' or 'angiotensin-converting enzyme') and ('COPD' or 'chronic obstructive pulmonary disease') and ('polymorphism' or 'SNP' or 'variant' or 'mutation'). We also checked the reference lists of identified reports for the other potentially relevant studies. The search strategy was completed by two authors (Guodong Xu and Guohui Fan). A final reference list was determined after combining search results and removing duplicated hits.

Selection criteria {#section8-1470320318770546}
------------------

Articles were included if the genotype or allele counts of the *ACE* gene I/D polymorphism were provided in both COPD patients and healthy controls, and if COPD was diagnosed by a standard method, and if the I/D polymorphism was genotyped by a validated method. Only articles published in the English language were included in this meta-analysis. An article was excluded if it was published in forms of conference abstract, letter to the editor, case reports or case series, or if it lacked the control group.

As per the selection criteria formulated above, two authors (Guodong Xu and Guohui Fan) independently assessed the eligibility of each potential article for inclusion, and the results were compared and disagreement was solved by consensus.

Data extraction {#section9-1470320318770546}
---------------

The following data were extracted into a uniform design table from each eligible study: the first author's surname, year of publication, country where the study was conducted, race of the study population, study design, diagnosis of COPD, source of controls, age, gender, body mass index, forced expiratory volume in one second (FEV~1~), FEV~1~/FVC (forced vital capacity), smoking status, pack years of smoking, the number of subjects with different genotypes of the *ACE* gene I/D polymorphism in COPD patients and controls. Data abstracted by the two authors were checked for coherence, and any divergence was resolved by resorting to original context until a consensus was reached.

Statistical analysis {#section10-1470320318770546}
--------------------

Statistical analyses were conducted using STATA/SE software (version 11.2 for Windows; Stata Corp, College Station, TX, USA).

The primary outcome was the weighted odds ratio (OR) with 95% confidence interval (CI) for different genotypes and alleles of the *ACE* gene I/D polymorphism in patients with COPD compared with controls. The second outcome of this meta-analysis was the discrepancies of FEV~1~ and circulating ACE between different genotypes, as expressed as weighted mean difference (WMD) with 95% CI. The summary OR and WMD were calculated with a fixed effects model. Heterogeneity was tested using the inconsistency index (*I^2^*) statistic (ranging from 0.0% to 100.0%), which is defined as the percentage of observed between-study variability that is due to heterogeneity rather than chance. If the *I^2^* exceeds 50.0%, it indicates statistically significant heterogeneity.

Funnel plots were used to assess the probability of publication bias and the small study effect. If funnel shape was asymmetric inverted, it might suggest an association between the pooled estimate and study size (publication bias or small study bias). The Egger's test was used to assess funnel asymmetry objectively.

Univariate random-effects meta-regressions with log-transformed ORs were used to assess potential confounding of some risk factors, including age, gender and proportion of smokers.

Results {#section11-1470320318770546}
=======

Qualifying studies {#section12-1470320318770546}
------------------

Our initial search of three public databases identified 42 articles published in the English language, and only 16 of them were eligible for analysis.^[@bibr6-1470320318770546][@bibr7-1470320318770546][@bibr8-1470320318770546]--[@bibr9-1470320318770546],\ [@bibr13-1470320318770546][@bibr14-1470320318770546][@bibr15-1470320318770546][@bibr16-1470320318770546][@bibr17-1470320318770546][@bibr18-1470320318770546][@bibr19-1470320318770546][@bibr20-1470320318770546][@bibr21-1470320318770546][@bibr22-1470320318770546][@bibr23-1470320318770546]--[@bibr24-1470320318770546]^ There were 12 articles (12 studies including 2113 patients and 8786 controls) that incorporated data on the risk of the *ACE* gene I/D polymorphism for COPD, and eight articles (14 studies including 11,664 subjects) that incorporated data on the changes of either FEV~1~ or FEV~1~/FEV or circulating ACE across the genotypes of this polymorphism.

Baseline characteristics {#section13-1470320318770546}
------------------------

The baseline characteristics of eligible studies are presented in both [Table 1](#table1-1470320318770546){ref-type="table"} and [Supplementary Table 2](http://journals.sagepub.com/doi/suppl/10.1177/1470320318770546).

###### 

Baseline characteristics of eligible studies for the association of *ACE* gene I/D polymorphism with COPD risk.

![](10.1177_1470320318770546-table1)

  First author      Year   Country    Race        Design            Match   Diagnosis   Source       Sample size   Age (years)   Gender (male)                   
  ----------------- ------ ---------- ----------- ----------------- ------- ----------- ------------ ------------- ------------- --------------- ------ -------- --------
  Mlak et al.       2016   Poland     Caucasian   Cross-sectional   n.a.    GOLD        Population   206           165           63.0            64.0   0.6796   0.6303
  Ayada et al.      2014   Turkey     Turkish     Cross-sectional   Yes     GOLD        Hospital     47            64            n.a.            n.a.   n.a.     n.a.
  Ulasli et al.     2013   Turkey     Caucasian   Cross-sectional   n.a.    GOLD        Hospital     50            49            64.0            54.6   0.9400   0.7959
  Simsek et al.     2013   Turkey     Turkish     Cross-sectional   n.a.    GOLD        Hospital     66            40            61.2            59.7   0.6364   0.7250
  Kuzubova et al.   2013   Russia     Caucasian   Cross-sectional   n.a.    GOLD        Population   63            95            60.4            57.3   1.0000   1.0000
  Pabst et al.      2009   Germany    Caucasian   Cross-sectional   n.a.    ATS/ERS     Population   152           158           62.8            63.9   0.6842   0.3924
  Lee et al.        2009   Denmark    Caucasian   Prospective       n.a.    GOLD        Population   1259          7775          n.a.            n.a.   0.5060   0.4319
  Zhang et al.      2008   China      Chinese     Cross-sectional   Yes     ATS/ERS     Hospital     61            57            63.0            61.6   0.8361   0.7719
  Busquets et al.   2007   Spain      Caucasian   Cross-sectional   n.a.    ATS/ERS     Population   74            159           74.0            56.0   1.0000   1.0000
  Tkacova et al.    2005   Slovakia   Caucasian   Cross-sectional   n.a.    GOLD        Hospital     66            118           65.4            63.5   0.7424   0.6780
  Ahsan et al.      2004   India      Indian      Cross-sectional   Yes     ATS/ERS     Hospital     27            66            n.a.            n.a.   1.0000   1.0000
  Yildiz et al.     2003   Turkey     Caucasian   Cross-sectional   Yes     ATS/ERS     Hospital     42            40            62.0            60.0   0.9762   1.0000

  --------------- ------------- ---------------------- ---------------------- ---------------- ---------- ---------- ---------- ------- ---------- ----- ----- ----- ------ ------ ------
  BMI (kg/m^2^)   Smoking (%)   Smoking (pack years)   FEV~1~ (% predicted)   FEV~1~/FVC (%)   Cases      Controls                                                                 
  Cases           Controls      Cases                  Controls               Cases            Controls   Cases      Controls   Cases   Controls   DD    ID    II    DD     ID     II
  27.0            28.4          0.9126                 0.9333                 41.50            43.30      45.40      n.a.       48.30   n.a.       60    99    47    51     73     41
  n.a.            n.a.          n.a.                   n.a.                   n.a.             n.a.       n.a.       n.a.       n.a.    n.a.       13    26    8     28     28     8
  25.8            28.9          n.a.                   0.0000                 57.20            n.a.       45.10      100.00     44.20   79.00      28    11    11    33     10     6
  n.a.            n.a.          n.a.                   0.0000                 55.12            n.a.       36.20      8.50       62.80   82.44      31    20    15    13     19     8
  n.a.            n.a.          1.0000                 0.5700                 32.80            n.a.       45.00      n.a.       n.a.    n.a.       17    29    17    22     49     24
  n.a.            n.a.          0.4803                 0.3354                 31.10            18.70      52.60      81.50      58.60   96.80      33    76    43    50     69     39
  n.a.            n.a.          0.8682                 0.7307                 n.a.             n.a.       n.a.       n.a.       n.a.    n.a.       336   609   314   2038   3876   1861
  23.9            25.1          n.a.                   n.a.                   n.a.             n.a.       n.a.       n.a.       n.a.    n.a.       13    27    21    9      28     20
  25.0            27.0          1.0000                 n.a.                   49.00            n.a.       44.00      n.a.       44.00   n.a.       27    40    7     53     79     27
  n.a.            n.a.          n.a.                   n.a.                   n.a.             n.a.       n.a.       n.a.       n.a.    n.a.       20    31    15    31     68     19
  n.a.            n.a.          1.0000                 1.0000                 n.a.             n.a.       n.a.       n.a.       n.a.    n.a.       5     12    10    10     33     23
  n.a.            n.a.          0.2381                 0.3000                 34.00            29.00      42.00      101.00     55.00   86.00      14    21    7     12     18     10
  --------------- ------------- ---------------------- ---------------------- ---------------- ---------- ---------- ---------- ------- ---------- ----- ----- ----- ------ ------ ------

ACE: angiotensin-converting enzyme; BMI: body mass index; FEV~1~: forced expiratory volume in one second; FVC: forced vital capacity; DD: deletion/deletion genotype; ID: insertion/deletion; II: insertion/insertion genotype; n.a.: not available.

I/D polymorphism and COPD risk: overall analysis {#section14-1470320318770546}
------------------------------------------------

The association of the *ACE* gene I/D polymorphism with COPD risk was examined under the allelic, homozygous genotypic and dominant models, respectively. [Figure 1](#fig1-1470320318770546){ref-type="fig"} shows the corresponding forest plots. Overall, no hint of statistical significance was noted between this polymorphism and COPD risk under all genetic models (*P*\>0.05). There was no evidence of heterogeneity between studies (*I*^2^=0.0%, 0.0% and 10.4%, respectively). In addition, there was a low likelihood of publication bias (Egger's test *P*=0.811, 0.994 and 0.894, respectively). The Begg's funnel plot in [Figure 2](#fig2-1470320318770546){ref-type="fig"} seemed symmetrical, and no study was reported to be missing.

![Forest plots of the angiotensin-converting enzyme (*ACE*) gene insertion/deletion (I/D) polymorphism in association with chronic obstructive pulmonary disease under allelic (the upper), homozygous genotypic (the middle) and dominant (the lower) models.](10.1177_1470320318770546-fig1){#fig1-1470320318770546}

![Begg's and filled funnel plots of the angiotensin-converting enzyme (*ACE*) gene insertion/deletion (I/D) polymorphism in association with chronic obstruction pulmonary disease under the allelic model.](10.1177_1470320318770546-fig2){#fig2-1470320318770546}

I/D polymorphism and COPD risk: subgroup analysis {#section15-1470320318770546}
-------------------------------------------------

[Table 2](#table2-1470320318770546){ref-type="table"} shows the subgroup analysis of the *ACE* gene I/D polymorphism in the prediction of COPD risk under the allelic, homozygous genotypic and dominant models, respectively. Factors under stratification included continent, race, study design, matched condition, COPD diagnosis, control source and sample size. Still, there was no detectable significance across all subgroups under all genetic models (*P*\>0.05), and there was low evidence of heterogeneity for a majority of comparisons (*I*^2^\<50%).

###### 

Subgroup analyses of ACE gene I/D polymorphisms in association with COPD.

![](10.1177_1470320318770546-table2)

  Subgroups              Studies (cases/controls)   Allele model (I vs. D)   Homozygous genotype model (II vs. DD)   Dominant model (II + ID vs. DD)                                                                                   
  ---------------------- -------------------------- ------------------------ --------------------------------------- --------------------------------- ------- ------ ------ ------ ------ ------- ------ ------ ------ ------ ------- ------
  ***Continent***                                                                                                                                                                                                                      
  Asia                   6 (293/316)                1.05                     0.83                                    1.33                              0.678   22.9   1.06   0.66   1.69   0.814   0.0    1.00   0.64   1.56   0.986   31.3
  Europe                 6 (1820/8470)              1.02                     0.94                                    1.09                              0.678   0.0    1.03   0.89   1.20   0.662   0.0    1.00   0.89   1.12   0.962   0.0
  ***Race***                                                                                                                                                                                                                           
  Caucasian              8 (1912/8559)              1.02                     0.95                                    1.10                              0.606   2.9    1.04   0.89   1.22   0.618   2.0    1.00   0.89   1.13   0.938   0.0
  Chinese                1 (61/57)                  0.98                     0.51                                    1.86                              0.631   n.a.   0.87   0.24   3.21   0.551   n.a.   0.79   0.24   2.56   0.443   n.a.
  Indian                 1 (27/66)                  0.88                     0.52                                    1.48                              0.941   n.a.   0.73   0.26   2.07   0.834   n.a.   0.69   0.27   1.77   0.689   n.a.
  Turkish                2 (113/104)                1.11                     0.75                                    1.64                              0.596   64.9   1.26   0.47   3.38   0.644   34.7   1.05   0.29   3.84   0.937   80.2
  ***Study design***                                                                                                                                                                                                                   
  Cross-sectional        11 (854/1011)              1.04                     0.91                                    1.19                              0.559   4.2    1.07   0.82   1.40   0.628   0.0    1.04   0.83   1.31   0.714   15.9
  Nested                 1 (1259/7775)              1.01                     0.93                                    1.10                              0.805   n.a.   1.02   0.87   1.21   0.785   n.a.   0.98   0.85   1.12   0.722   n.a.
  ***Matched***                                                                                                                                                                                                                        
  Yes                    4 (177/227)                1.02                     0.77                                    1.36                              0.867   5.9    0.95   0.52   1.71   0.856   0.0    1.05   0.62   1.79   0.845   19.7
  No                     8 (1936/8559)              1.02                     0.95                                    1.10                              0.621   5.1    1.04   0.90   1.20   0.585   0.0    1.01   0.85   1.20   0.908   17.2
  ***COPD diagnosis***                                                                                                                                                                                                                 
  ATS/ERS                5 (356/480)                1.01                     0.82                                    1.23                              0.946   17.1   0.90   0.54   1.51   0.683   29.1   1.05   0.74   1.51   0.776   15.0
  GOLD                   7 (1757/8306)              1.02                     0.95                                    1.10                              0.595   0.0    1.04   0.90   1.21   0.582   0.0    1.00   0.82   1.22   0.974   17.8
  ***Control source***                                                                                                                                                                                                                 
  Hospital               7 (359/434)                1.05                     0.86                                    1.29                              0.632   7.5    1.09   0.72   1.65   0.675   0.0    0.97   0.67   1.39   0.855   21.0
  Population             5 (1754/8352)              1.01                     0.94                                    1.09                              0.705   0.0    1.03   0.83   1.27   0.781   12.6   1.03   0.86   1.22   0.773   13.9
  ***Sample size***                                                                                                                                                                                                                    
  \<158                  6 (293/320)                1.05                     0.83                                    1.33                              0.678   22.9   1.06   0.66   1.69   0.814   0.0    1.00   0.64   1.56   0.986   31.3
  ≥158                   6 (1820/8470)              1.02                     0.94                                    1.09                              0.678   0.0    1.04   0.90   1.19   0.662   0.0    1.00   0.89   1.12   0.962   0.0

ACE: angiotensin-converting enzyme; COPD: chronic obstructive pulmonary disease; OR: odds ratio; 95% CI: 95% confidence interval; *I*^2^: inconsistency index; I: insertion allele; D: deletion allele; DD: deletion/deletion genotype; ID: insertion/deletion; II: insertion/insertion genotype; II: insertion/insertion genotype; n.a.: not available.

I/D polymorphism and COPD risk: meta-regression analysis {#section16-1470320318770546}
--------------------------------------------------------

Other sources of heterogeneity were explored through meta-regression analysis, including age, gender, smoking and pack years of smoking, and no factors exhibited a significant contribution (*P*\>0.05).

I/D polymorphism and phenotypes: overall analysis {#section17-1470320318770546}
-------------------------------------------------

[Table 3](#table3-1470320318770546){ref-type="table"} shows the changes in FEV~1~, FEV~1~/FVC and circulating ACE across genotypes of the *ACE* gene I/D polymorphism. Carriers of the II genotype, ID genotype and the combination of II and ID genotypes had significantly lower levels of circulating ACE than those with the DD genotype (WMD −13.35, −8.13 and −10.74 U/L, respectively, all *P*\<0.001). For FEV~1~/FVC, carriers of the ID genotype had a marginally lower level than those with the DD genotype (WMD −1.66, *P*=0.034). There was no evidence of heterogeneity and publication bias, as reflected by the *I*^2^ and Egger's test, respectively.

###### 

Mean changes of FEV~1~, FEV~1~/FVC and circualting ACE between carriers of different genotypes of *ACE* gene I/D polymorphism.

![](10.1177_1470320318770546-table3)

  Comparison             Studies   WMD      95% CI lower   95% CI upper   *P* value   *I* ^2^   Egger's *P* value
  ---------------------- --------- -------- -------------- -------------- ----------- --------- -------------------
  ***II vs. DD***                                                                               
  FEV~1~                 7         0.03     −0.77          0.83           0.937       0.0%      0.974
  FEV~1~/FVC             2         0.04     −2.43          2.50           0.978       0.0%      n.a.
  Circulating ACE        5         −13.35   −14.58         −12.12         \<0.001     0.0%      0.272
  ***ID vs. DD***                                                                               
  FEV~1~                 7         0.01     −0.65          0.68           0.971       0.0%      0.641
  FEV~1~/FVC             2         −1.66    −3.19          −0.13          0.034       0.0%      n.a.
  Circulating ACE        5         −8.13    −10.16         −6.09          \<0.001     24.5%     0.182
  ***II + ID vs. DD***                                                                          
  FEV~1~                 7         −0.04    −0.59          0.66           0.911       0.0%      0.879
  FEV~1~/FVC             2         −0.74    −2.23          0.76           0.334       0.0%      n.a.
  Circulating ACE        5         −10.74   −12.32         −9.15          \<0.001     15.1%     0.215

ACE: angiotensin-converting enzyme; WMD: weighted mean difference; 95% CI: 95% confidence interval; *I*^2^: inconsistency index; DD: deletion/deletion genotype; ID: insertion/deletion; II: insertion/insertion genotype; FEV~1~: forced expiratory volume in one second; FVC: forced vital capacity; n.a.: not available.

I/D polymorphism and phenotypes: subgroup analysis {#section18-1470320318770546}
--------------------------------------------------

Shown in [Table 4](#table4-1470320318770546){ref-type="table"} is the subgroup analysis of relevant phenotypes across genotypes of the *ACE* gene I/D polymorphism under various genetic models. According to the degree of FEV~1~/predicted FEV~1~ in DD genotype carriers, no significant association was found in COPD patients and controls, respectively. When FEV~1~ of 50% or greater predicted FEV~1~, FEV~1~ was marginally lower in the ID genotype carriers than the DD genotype carriers (WMD −1.73, *P*=0.056).

###### 

Subgroup analyses of FEV~1~/predicted FEV~1~ and circulating ACE between carriers of different genotypes of *ACE* gene I/D polymorphism.

![](10.1177_1470320318770546-table4)

  Subgroup                        Studies   II vs. DD   ID vs. DD   II + ID vs. DD                                                                                                  
  ------------------------------- --------- ----------- ----------- ---------------- --------- ------ ------- -------- ------- --------- ------ -------- -------- ------- --------- ------
  ***FEV~1~/predicted FEV~1~***                                                                                                                                                     
  Patients                        6         −0.39       −2.08       1.30             0.652     0.0    −0.81   −2.15    0.52    0.234     0.0    −0.44    −1.71    0.82    0.495     0.0
  FEV~1~ ≥50% predicted           3         −1.05       −3.07       0.96             0.305     0.0    −1.73   −3.50    0.04    0.056     0.0    −1.38    −3.03    0.27    0.101     0.0
  FEV~1~ \<50% predicted          3         1.18        −1.92       4.28             0.455     0.0    0.39    −1.64    2.43    0.705     0.0    0.91     −1.07    2.89    0.368     0.0
  Controls                        1         −2.70       −12.77      7.37             0.599     n.a.   −8.60   −18.62   1.42    0.092     n.a.   −5.65    −14.36   3.06    0.203     n.a.
  ***Circulating ACE***                                                                                                                                                             
  Patients                        2         −14.03      −16.47      −11.59           \<0.001   0.0    −9.00   −11.51   −6.49   \<0.001   0.0    −11.52   −13.73   −9.31   \<0.001   0.0
  Control                         3         −13.12      −14.54      −11.69           \<0.001   37.7   −7.20   −8.63    −5.77   \<0.001   47.4   −10.14   −11.49   −8.79   \<0.001   43.6

ACE: angiotensin-converting enzyme; WMD: weighted mean difference; 95% CI: 95% confidence interval; DD: deletion/deletion genotype; ID: insertion/deletion; II: insertion/insertion genotype; FEV~1~: forced expiratory volume in one second; n.a.: not available.

In the case of circulating ACE, changes were consistently significant in both COPD patients and controls, and it was more obvious for the comparison of the II genotype with the DD genotype (WMD −14.03 U/L, *P*\<0.001 in patients and WMD −13.12, *P*\<0.001 in controls).

Discussion {#section19-1470320318770546}
==========

This meta-analysis was designed to examine the association of the *ACE* gene I/D polymorphism with COPD risk. After a comprehensive analysis of 16 articles, our findings demonstrated that the *ACE* gene I/D polymorphism was not associated with the risk of COPD. In addition, we observed that the ID genotype carriers of this polymorphism tended to have reduced FEV~1~ (% predicted FEV~1~) in COPD patients with GOLD stages I--II. To our knowledge, this is the first meta-analytical report that has evaluated the association of the *ACE* gene I/D polymorphism with pulmonary function.

COPD is a complex multifactorial disease, and its development is thought to be largely under genetic control. A considerable number of genes and polymorphisms have been identified as susceptible candidates for COPD risk.^[@bibr25-1470320318770546][@bibr26-1470320318770546]--[@bibr27-1470320318770546]^ The gene encoding ACE is one such candidate. ACE is a key element of the renin--angiotensin--aldosterone system, and its plasma levels are modulated by common defects of the gene.^[@bibr28-1470320318770546]^ In particular, the *ACE* gene I/D polymorphism has received great attention, as the D allele of this polymorphism correlated with a higher plasma ACE activity, the finding being further validated by our current analysis on different genetic models and diverse disease conditions. It has recently been increasingly recognised that the *ACE* gene I allele, interacting with the endothelial nitric oxide synthase (*eNOS*) gene 894G allele, can cause less vasoconstriction and increase vasodilation that may be advantageous in the improvement of COPD.^[@bibr14-1470320318770546]^ However, in the present meta-analysis, although the *ACE* gene I allele was associated with a slightly increased risk of COPD, there was no detectable significance under different genetic models of inheritance, even in various subgroups by many study characteristics. This association was robust and solid, as this meta-analysis is currently based on the largest number of eligible studies relative to previously published meta-analyses,^[@bibr29-1470320318770546][@bibr30-1470320318770546]--[@bibr31-1470320318770546]^ and importantly our findings remain unperturbed by between-study heterogeneity and publication bias. On the other hand, it is widely recognised that the increased risk attributable to a single allele is small in genetically susceptible individuals, and such a small effect may also be exacerbated by locus heterogeneity across different ethnic/racial groups.^[@bibr6-1470320318770546],[@bibr8-1470320318770546],[@bibr18-1470320318770546]^ Wide coverage of the genetic variability of the *ACE* gene and other COPD susceptibility genes is required to decipher the genetic basis of COPD.

In addition, our findings also dropped a hint of a probable contribution of the *ACE* gene I/D polymorphism to pulmonary function, as carriers of the ID genotype had a significantly lower level of FEV~1~/FVC than carriers of the DD genotype. Moreover, the ID genotype was associated with reduced FEV~1~ in COPD patients with GOLD stages I--II, while this reduction was non-significant in patients with GOLD stages III--IV. In view of limited studies in subgroup analysis, our findings gave rise to speculation that the *ACE* gene I/D polymorphism may serve as a predictive marker for the early development of COPD. We agree that further validation of our findings in large, well-designed studies is necessary.

Our analyses have several limitations. The first limitation was that our findings were based on cross-sectional observational data, which precluded comment on causality between circulating ACE and COPD risk. The second limitation lay in the analysis of only one polymorphism in the *ACE* gene. The third limitation was that we only retrieved articles published in the English language, as it is estimated that the exclusion of grey literature from meta-analysis may result in an overestimate of an association impact by an average of 12%.^[@bibr32-1470320318770546]^ The fourth limitation was although our analyses indicated low probabilities of heterogeneity and publication bias, we cannot fully exclude their potential confounding impact. The fifth limitation was that residual confounding due to unadjusted divergence in baseline characteristics of eligible studies cannot be completely assessed or ruled out using study-level data.

Taken together, our meta-analytical findings demonstrated that the *ACE* gene I/D polymorphism was not associated with the risk of COPD. Large-scale validation is necessary to confirm our findings. For practical reasons, a single well-designed study is warranted to interrogate gene--gene and gene--environment interactions further on the association of *ACE* gene multiple polymorphisms with COPD risk and related pulmonary phenotypes.
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